
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings showcases a positive outlook due to a robust 5% increase in request for proposals (RFP) flow across all market segments, particularly strong within the early stage operations, suggesting a favorable demand environment. The company’s ability to capitalize on this demand is further underscored by a 5.5% growth in backlog, indicating a solid pipeline for future revenue growth as it stabilizes. Additionally, IQVIA's strategic plan to deploy $2 billion in capital for mergers and acquisitions and share repurchases in 2025, combined with anticipated revenue growth of 4-7% in its Research & Development Services segment, reinforces the optimistic outlook for the company going forward.
Bears say
IQVIA Holdings Inc. faces a challenging financial outlook due to prolonged COVID-related impacts, rising interest expenses, and a deteriorating funding environment in the biopharma sector, which has adversely affected investor sentiment and earnings per share (EPS) growth since the first quarter of 2022. The company's backlog has remained flat, compounded by foreign exchange headwinds leading to a significant downward revision of previously reported backlog figures, indicating potential difficulties in securing new contracts. Furthermore, a competitive pricing landscape and declining gross margins—driven by revenue mix and increased costs from delayed trials—are likely to hinder growth prospects and contribute to ongoing earnings pressure amidst an uncertain macroeconomic environment.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares